Table 3.

Subgroup analysis between baseline characteristics and virological response rates

Subgroup	SVR12 not achieved, n (%)	SVR12 achieved, n (%)	SVR12 rate % (95% CI)
Sex
Male (N = 172)	4	168	97.7% (94.2%, 99.4%)
Female (N = 154)	1	153	99.4% (96.4%, 100.0%)
HCV genotype
GT-1a (N = 3)	0	3	100% (29.2%, 100.0%)
GT-1b (N = 166)	2	164	98.8% (95.7%, 99.9%)
GT-2a (N = 95)	0	95	100% (96.2%, 100.0%)
GT-3a (N = 16)	1	15	93.8% (69.8%, 99.8%)
GT-3b (N = 6)	0	6	100% (54.1%, 100.0%)
GT-6a (N = 34)	1	33	97.1% (84.7%, 99.9%)
GT-6n (N = 6)	1	5	83.3% (35.9%, 99.6%)
IL28B genotype
CC (N = 271)	4	267	98.5% (96.3%, 99.6%)
Non-CC (N = 55)	1	54	98.2% (90.3%, 100.0%)
Previous treatment history of interferon
No (N = 23)	1	22	95.7% (78.1%, 99.9%)
Yes (N = 303)	4	299	98.7% (96.7%, 99.6%)
Cirrhosis
No (N = 285)	2	283	99.3% (97.5%, 99.9%)
Yes (N = 41)	3	38	92.7% (80.1%, 98.5%)
Age, years
≥ 18 and < 40 (N = 61)	0	61	100% (94.1%, 100.0%)
≥ 40 and < 65 (N = 235)	5	230	97.9% (95.1%, 99.3%)
≥ 65 (N = 30)	0	30	100% (88.4%, 100.0%)
Body mass index, kg/m2
< 25 (N = 198)	1	197	99.5% (97.2%, 100.0%)
≥ 25 and < 30 (N = 122)	4	118	96.7% (91.8%, 99.1%)
≥ 30 (N = 6)	0	6	100% (54.1%, 100.0%)
Baseline HCV RNA (IU/mL) classification 1
< 2 × 106 (N = 146)	1	145	99.3% (96.2%, 100.0%)
≥ 2 × 106 (N = 180)	4	176	97.8% (94.4%, 99.4%)
Classification 2
< 6 × 106 (N = 238)	2	236	99.2% (97.0%, 99.9%)
≥ 6 × 106 (N = 88)	3	85	96.6% (90.4%, 99.3%)
Baseline ALT (IU/L)
< 1.5 × ULN (N = 0)	–	–	–
≥ 1.5 × ULN (N = 326)	5	321	98.5% (96.5%, 99.5%)
Baseline CLcr (mL/min)
< 60 (N = 7)	0	7	100% (59.0%, 100.0%)
≥ 60 and < 90 (N = 74)	1	73	98.6% (92.7%, 100.0%)
≥ 90 (N = 245)	4	241	98.4% (95.9%, 99.6%)